Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ENT advisory panel

This article was originally published in The Gray Sheet

Executive Summary

FDA's Ear, Nose and Throat advisory panel will vote on a premarket approval application for Symphonix' Vibrant Soundbridge semi-implantable hearing device designed to treat moderate to severe sensorineural hearing loss, the most common form of hearing impairment, at a meeting July 20-21 in Gaithersburg, Maryland. The committee also will review an application for an implant intended to restore useful hearing to individuals with Neurofibromatosis Type II who have become deaf as a result of surgery to remove bilateral auditory nerve tumors
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT013596

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel